Verrica Pharmaceuticals I... (VRCA)
0.42
-0.02 (-4.20%)
At close: Apr 03, 2025, 3:59 PM
0.41
-2.40%
After-hours: Apr 03, 2025, 04:23 PM EDT
-4.20% (1D)
| Bid | 0.39 |
| Market Cap | 38.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.48 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | -1.2 |
| Analyst | Hold |
| Ask | 0.45 |
| Volume | 337,739 |
| Avg. Volume (20D) | 379,695 |
| Open | 0.42 |
| Previous Close | 0.44 |
| Day's Range | 0.39 - 0.43 |
| 52-Week Range | 0.39 - 11.41 |
| Beta | 1.45 |
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based p...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 2018
Employees 71
Stock Exchange NASDAQ
Ticker Symbol VRCA
Website https://www.verrica.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VRCA stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 1337.47% from the latest price.
Stock ForecastsNext Earnings Release
Verrica Pharmaceuticals Inc. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-7.56%
Verrica Pharmaceuticals shares are trading lower. ...
Unlock content with
Pro Subscription
4 months ago
-0.29%
Verrica Pharmaceuticals shares are trading lower after the company announced a proposed public offering.
